

Clinical trial results:

A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome

EudraCT number	2014-004383-37	
Trial protocol	Outside EU/EEA	
Global end of trial date	30 April 2014	
Results information		
Result version number	v1 (current)	
This version publication date	30 June 2016	
First version publication date	03 July 2015	

Trial information

Trial identification	
Sponsor protocol code	SP1004
Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01495793
WHO universal trial number (UTN)	-

Notes:

Sponsors	
Sponsor organisation name	UCB Biosciences Inc.
Sponsor organisation address	8010 Arco Corporate Drive, Raleigh, United States, NC 27617
Public contact	CTRRD, UCB Biosciences GmbH, +49 2173481515, clinicaltrials@ucb.com
Scientific contact	CTRRD, UCB Biosciences GmbH, +49 2173481515, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage	
Analysis stage	Final
Date of interim/final analysis	13 August 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 April 2014
Global end of trial reached?	Yes
Global end of trial date	30 April 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to determine the pharmacokinetic (PK) properties of rotigotine in adolescents with idiopathic restless legs syndrome (RLS) after multiple patch administrations.

Protection of trial subjects:

Close monitoring of subjects safety status, including checks of mental health e.g. by CSSR-S questionnaire.

Background therapy:

If nausea or vomiting occurred during the study, antiemetic therapy with ondansetron was allowed. Ondansetron was not to be used prophylactically. Use of a topical anesthetic was permitted to treat the venous puncture or indwelling venous catheter site prior to the needle stick. If medication is medically indicated, the subject must inform the investigator immediately. All concomitant medication and treatment was recorded in the appropriate study documents (i.e. eCRF and source document).

Evidence for comparator:

Not applicable

Actual start date of recruitment	01 December 2011
Long term follow-up planned	No
Independent data monitoring committee	No
(IDMC) involvement?	

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 24
Worldwide total number of subjects	24
EEA total number of subjects	0

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	24
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This was a multicenter study in which 42 subjects were enrolled and 24 treated at 8 sites in the USA.

Pre-assignment

Screening details:

In total 42 subjects signed the informed consent and were enrolled into the study (Enrolled Set). 24 of these subjects were treated with medication. The sample size of 24 subjects was sufficient to target a 95% confidence interval and the calculation was based on a previous study. Participant Flow refers to the 24 treated subjects (Safety Set).

Period :	1
----------	---

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Rotigotine

Arm description:

In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Neupro 0.5 mg/24 h
Investigational medicinal product code	Prod 1
Other name	
Pharmaceutical forms	Transdermal patch
Routes of administration	Transdermal use

Dosage and administration details:

In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.

Dose (size): 0.5 mg/24 h (2.5 cm^2)

The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.

Investigational medicinal product name	Neupro 1 mg/24 h
Investigational medicinal product code	Prod 2
Other name	
Pharmaceutical forms	Transdermal patch
Routes of administration	Transdermal use

Dosage and administration details:

In the Titration Period a subject received the first dose of rotigotine than the dose was increased weekly by a dose step over 4 weeks.

Dose (size): 1 mg/24 h (5 cm^2)

The patch has to be worn continuously for 24h. After 24h, the patch has to be removed and a new one applied.

_ · ·	
Investigational medicinal product name	Neupro 3 mg/24 h
Investigational medicinal product code	Prod 4
Other name	
Pharmaceutical forms	Transdermal patch
Routes of administration	Transdermal use

Dosage and administration details:

In the Titration Period a subject received the first dose of rotigotine than the dose was increased weekly by a dose step over 4 weeks.

Dose (size): 3 mg/24 h (15 cm^2)

The patch has to be worn continuously for 24h. After 24h, the patch has to be removed and a new one applied.

_ ' ' '	
Investigational medicinal product name	Neupro 2 mg/24 h
Investigational medicinal product code	Prod 3
Other name	
Pharmaceutical forms	Transdermal patch
Routes of administration	Transdermal use

Dosage and administration details:

In the Titration Period a subject received the first dose of rotigotine than the dose was increased weekly by a dose step over 4 weeks.

Dose (size): 2 mg/24 h (10 cm^2

The patch has to be worn continuously for 24h. After 24h, the patch has to be removed and a new one applied.

Number of subjects in period 1	Rotigotine
Started	24
Completed	22
Not completed	2
Lost to follow-up	1
Violation of inclusion criteria	1

5HSRUWLQJ JURXSV

5HSRUWLQJ JURXS GHVFULSWLRQ

5HSRUWLQJ JURXS WLWOH | 5RWLJRWLQH

,Q WKH 7LWUDWLRQ 3HULRG D VXEMHFW UHFHLYHG WKH ILUVW GRVH RI URWLJRW E\ D GRVH VWHS RYHU ZHHNV

	50.001.10.001	011 701100	
5HSRUWLQJ JURXS YDOX	HV SRWLJRWL	QH 7RWDO	
1XPEHU RI VXEMHFWV			
\$JH FDWHJRULFDO			
8QLWV 6XEMHFWV			
\ H D U V			
\ H D U V			
\ H D U V			
\ H D U V			
\ H D U V			
\$JH &RQWLQXRXV			
8QLWV \HDUV			
DULWKPHWLF PHDQ			
VWDQGDUG GHYLDWLRQ	"		
*HQGHU &DWHJRULFDO			
8QLWV 6XEMHFWV			
0 D O H			
) H P D O H			
5DFH 1,+ 20%			
8QLWV 6XEMHFWV			
\$PHULFDQ ,QGLDQ RU \$0	DVND 1DWLYH		
\$VLDQ			
%ODFN RU \$IULFDQ \$PHI	JLFDQ		
1DWLYH +DZDLLDQ RU 2	WKHU 3DFLILF		
, V O D Q G H U			
:KLWH			
ORUH WKDQ RQH UDFH			
8QNQRZQ RU 1RW 5HSRL	WHG		
(WKQLFLW\ 1,+ 20%			
8QLWV 6XEMHFWV			
1RW +LVSDQLF RU /DWL	N K		
+LVSDQLF RU /DWLQR			
8QNQRZQ RU 1RW 5HSRL	WHG		
+ H L J K W			
8QLWV FP			
DULWKPHWLF PHDQ			
VWDQGDUG GHYLDWLRQ	"		
HLJKW			
8QLWV NJ			
DULWKPHWLF PHDQ			
VWDQGDUG GHYLDWLRQ	"		
%0, %RG\0DVV,QGH[

Units: kg/m^2			
arithmetic mean	23.388		
standard deviation	± 3.133	-	

End points

End points reporting groups

Reporting group title	Rotigotine

Reporting group description:

In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.

Subject analysis set title	Rotigotine (PKPPS)
Subject analysis set type	Per protocol

Subject analysis set description:

The Pharmacokinetic Per Protocol Set (PKPPS) includes all enrolled subjects who were included in the Safety Set, who had no protocol deviations that were considered to impact the subject's validity for analysis of the primary study objective and who for at least 1 dose step fulfilled specific predefined conditions.

Primary: Apparent Total Body Clearance (Cl/f) of unconjugated rotigotine 0.5 mg/24 h (2.5 cm^2)

End point title	Apparent Total Body Clearance (CI/f) of unconjugated
	rotigotine 0.5 mg/24 h (2.5 cm^2)[1]

End point description:

CL/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type	Primary
- 1 7 1	- <i>I</i>

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	6		
Units: L/h (liter per hour)			
least squares mean (confidence interval 95%)			
Apparent Total Body Clearance	676.86 (408.5 to 1121.51)		

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Total Body Clearance (Cl/f) of unconjugated rotigotine 1 mg/24 h (5 cm^2)

End point title	Apparent Total Body Clearance (Cl/f) of unconjugated
	rotigotine 1 mg/24 h (5 cm^2) ^[2]

End point description:

CL/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type Primary

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	10		
Units: L/h (Liter per hour)			
least squares mean (confidence interval 95%)			
Apparent Total Body Clearance	671.72 (459.11 to 982.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Total Body Clearance (Cl/f) of unconjugated rotigotine 2 mg/24 h (10 cm^2)

End point title	Apparent Total Body Clearance (Cl/f) of unconjugated
	rotigotine 2 mg/24 h (10 cm^2)[3]

End point description:

CL/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type Primary

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	11		
Units: L/h (Liter per hour)			
least squares mean (confidence interval 95%)			
Apparent Total Body Clearance	937.56 (658.5 to 1334.89)		

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Total Body Clearance (Cl/f) of unconjugated rotigotine 3 mg/24 h (15 cm^2)

End point title	Apparent Total Body Clearance (Cl/f) of unconjugated
	rotigotine 3 mg/24 h (15 cm^2) ^[4]

End point description:

CL/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type	Primary
Ziia poiite type	i i i i i i i i i i i i i i i i i i i

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	9		
Units: L/h (Liter per hour)			
least squares mean (confidence interval 95%)			
Apparent Total Body Clearance	1088.77 (723.47 to 1638.53)		

Statistical analyses

No statistical analyses for this end point

Primary: Volume of Distribution at steady state (VSS/f) of unconjugated rotigotine 0.5 mg/24 h (2.5 cm^2)

End point title	Volume of Distribution at steady state (VSS/f) of unconjugated
	rotigotine 0.5 mg/24 h (2.5 cm^2) ^[5]

EU-CTR publication date: 30 June 2016

End point description:

VSS/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type Primary

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	6		
Units: L (Liter)			
least squares mean (confidence interval 95%)			
Volume of Distribution at steady state	5403.16 (2850.67 to 10241.17)		

Statistical analyses

No statistical analyses for this end point

Primary: Volume of Distribution at steady state (VSS/f) of unconjugated rotigotine 1 mg/24 h (5 cm^2)

End point title Volun	e of Distribution at steady state (VSS/f) of unconjugated
rotigo	tine 1 mg/24 h (5 cm^2) ^[6]

End point description:

VSS/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type Primary

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	10		
Units: L (Liter)			
least squares mean (confidence interval 95%)			
Volume of Distribution at steady state	6220.79 (3842.05 to 10072.28)		

Statistical analyses

No statistical analyses for this end point

Primary: Volume of Distribution at steady state (VSS/f) of unconjugated rotigotine 2 mg/24 h (10 cm^2)

End point title	Volume of Distribution at steady state (VSS/f) of unconjugated
	rotigotine 2 mg/24 h (10 cm^2) ^[7]

End point description:

VSS/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type Primary

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	11		
Units: L (Liter)			
least squares mean (confidence interval 95%)			
Volume of Distribution at steady state	7114.01 (4547.88 to 11128.07)		

Statistical analyses

No statistical analyses for this end point

Primary: Volume of Distribution at steady state (VSS/f) of unconjugated rotigotine $3 \text{ mg}/24 \text{ h} (15 \text{ cm}^2)$

End point title	Volume of Distribution at steady state (VSS/f) of unconjugated

EU-CTR publication date: 30 June 2016

rotigotine 3 mg/24 h (15 cm^2)[8]

End point description:

VSS/f was calculated for each subject treated with rotigotine derived from the concentrations of unconjugated rotigotine measured in plasma.

For the primary variables the parametric point estimator for each dose step and the 95% CI was calculated using the least-squares (LS) means and the root mean square of error from the ANOVA of the log-transformed data with subsequent exponential transformation.

End point type	I During a un /
FOO DOINI IVDE	IPHIMARY
Life point type	i i i i i i i i i i i i i i i i i i i

End point timeframe:

0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on Day 7, 14, 21 and 28

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

End point values	Rotigotine (PKPPS)		
Subject group type	Subject analysis set		
Number of subjects analysed	9		
Units: L (Liter)			
least squares mean (confidence interval 95%)			
Volume of Distribution at steady state	6037.92 (3598.36 to 10131.41)		

EU-CTR publication date: 30 June 2016

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

This summary includes TEAEs from the Titration period, Taper period and Safety Follow-up (Day 1 up to

69 days).		
Assessment type	Non-systematic	
Dictionary used		
Dictionary name	MedDRA	
Dictionary version	9.1	
Reporting groups		
	I	

Reporting group title Rotigotine

Reporting group description:

In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.

Serious adverse events	Rotigotine	
Total subjects affected by serious adverse events		
subjects affected / exposed	0 / 24 (0.00%)	
number of deaths (all causes)	0	
number of deaths resulting from adverse events	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Rotigotine	
Total subjects affected by non-serious adverse events		
subjects affected / exposed	15 / 24 (62.50%)	
Investigations		
Blood bilirubin increased		
subjects affected / exposed	2 / 24 (8.33%)	
occurrences (all)	2	
Injury, poisoning and procedural complications		
Stress fracture		
subjects affected / exposed	1 / 24 (4.17%)	
occurrences (all)	1	
Animal bite		
subjects affected / exposed	1 / 24 (4.17%)	
occurrences (all)	1	

Road traffic accident			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Wound			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Nervous system disorders Somnolence			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
	_		
Syncope subjects affected / exposed			
	1 / 24 (4.17%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Migraine			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Dizzines subjects affected / exposed	2 / 24 (9 220/.)		
occurrences (all)	2 / 24 (8.33%)		
decarrences (any	2		
Sudden onset of sleep			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	2		
General disorders and administration			
site conditions Application site pruritus			
subjects affected / exposed	4 / 24 (16.67%)		
occurrences (all)	4		
Application site irritation			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Irritability			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Immune system disorders			
Tammana 3, occini disorders	I	I	l

Allergy to arthropod sting	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	1
Į , , ,	_
Food allergy	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	1
Gastrointestinal disorders	
Diarrhoea	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	
occurrences (aii)	1
Nausea	
subjects affected / exposed	7 / 24 (29.17%)
occurrences (all)	11
, ,	**
Vomiting	
subjects affected / exposed	2 / 24 (8.33%)
occurrences (all)	2
Reproductive system and breast disorders	
Dysmenorrhoea	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	1
,	<u> </u>
Skin and subcutaneous tissue disorders	
Acne	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	1
Untinguin	
Urticaria subjects affected / exposed	1 / 24 /4 170/)
	1 / 24 (4.17%)
occurrences (all)	1
Musculoskeletal and connective tissue	
disorders	
Arthralgia	
subjects affected / exposed	1 / 24 (4.17%)
occurrences (all)	1
Muscular weakness	
Muscular weakness subjects affected / exposed	1 / 24 /4 170/\
	1 / 24 (4.17%)
occurrences (all)	1
Musculoskeletal chest pain	
. Idocatosticida chest patri	1

1	ı	i	1
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
	_		
Muscukoseletal pain			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
	1		
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
For and in Continu			
Fungal infection			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
	_		
Nasopharyngitis			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	3		
Dhaminaitia			
Pharyngitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
	_		
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)			
occurrences (all)	1		
Increased appetite			
Increased appende	I		

subjects affected / exposed	1 / 24 (4.17%)	
occurrences (all)	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 March 2011	The main purpose of this substantial amendment was to include the suicidality risk assessment (Columbia-Suicide Severity Rating Scale [C-SSRS]). In accordance with the FDA draft Guidance for Industry, which went into effect on 29 Oct 2010. In addition, a list of anticipated serious adverse events (SAEs) was included in this amendment in compliance with the recent FDA guidance on safety reporting requirements for studies conducted under an open Investigational New Drug Application. The Beck Depression Inventory II and the Beck Anxiety Inventory were removed from the study assessments. Other changes included in this amendment were as follows: - Procedures for subjects wishing to enter the open-label, LTFU study (SP1005) following dose de-escalation but prior to the SFU Visit were added. - Definition of clinically relevant renal dysfunction at Visit 1/Screening Period as an exclusion criterion was increased from serum creatinine >1.0mg/dL to >1.5mg/dL since the previous serum creatinine level >1.0mg/dL was within the central laboratory's normal range. Physical examination was removed as a safety variable. - The version number of the Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale was added. - For clarity, a dose de-escalation table (Table 3-3) was added. - Storage requirements for the rotigotine patch were updated. - Use of a topical anesthetic prior to the needle stick was permitted. - Corrections were made to the definitions of some PK parameters, as well as the preparation and handling of the blood and saliva PK samples. - Reference to patch size was removed from all sections, except Section 7.1 of the protocol, Description of investigational medicinal product (IMP). - Vital sign parameters to be measured were specified as pulse rate, SBP, DBP, and orthostatic hypertension assessments. - Sponsor Clinical Project Manager contact information was updated. - Typographic errors and changes of an editorial nature were made.
19 September 2011	The purpose of this substantial amendment was to increase the minimum weight for enrollment in the study from 30kg to 40kg. An additional change clarifying that subjects must tolerate the first dose step to be able to transition into the open-label, LTFU study was also made.
02 May 2012	The main purpose of this substantial amendment was to ensure consistency between the protocol and the FDA Pediatric Development Plan for the RLS indication in subjects 13 to <18 years of age. Since the subject's dosing was no longer dependent on body weight, the dosing schedules for each study period were revised. The primary PK variables were changed to reflect those that were requested by the FDA for the revised sample size calculation. In addition, PK saliva sampling was removed from the study. Data from a recently completed PK study (RL0002) suggest that saliva concentrations of rotigotine cannot be used as a surrogate for plasma concentrations of rotigotine. Other changes included in this amendment were as follows: - Updated contact information for SAE reporting and procedures for reporting SAEs to be consistent with the current protocol template. - Updated the regulatory status of rotigotine for the treatment of RLS in adults in the US. - Removed the requirement for the PK blood samples to be centrifuged at a controlled temperature. - Corrected typographic errors and minor inconsistencies of an editorial nature.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

EU-CTR publication date: 30 June 2016